Ramezani Amitis, Velayati Ali Akbar, Roshan Mohammad Reza Hasanjani, Gachkar Latif, Banifazl Mohammad, Keyvani Hossein, Aghakhani Arezoo
Clinical Research Department, Pasteur Institute of Iran, No. 69, Pasteur Ave., Tehran, Iran.
Int J Infect Dis. 2008 May;12(3):252-5. doi: 10.1016/j.ijid.2007.08.003. Epub 2007 Oct 22.
Lamivudine is used for the treatment of chronic hepatitis B patients. Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients. In this study we aimed to determine the rate of YMDD motif mutants in lamivudine-untreated chronic hepatitis B patients in Iran.
A total of 77 chronic hepatitis B patients who had not been treated with lamivudine were included in the study. Serum samples from patients were tested by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for detection of YMDD motif mutants. All patients were also tested for liver enzymes, anti-HCV, HBeAg, and anti-HBe.
Of the 77 patients enrolled in the study, 73% were male and 27% were female. Mean ALT and AST levels were 124.4+/-73.4 and 103.1+/-81 IU/l, respectively. HBeAg was positive in 40% and anti-HBe in 60% of the patients. Anti-HCV was negative in all of them. YMDD motif mutants were not detected in any of the patients despite the liver enzyme levels and the presence of HBeAg or anti-HBe.
Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients.
拉米夫定用于治疗慢性乙型肝炎患者。最近的研究表明，YMDD基序突变体（耐药乙型肝炎病毒）作为自然基因组变异出现在未接受拉米夫定治疗的慢性乙型肝炎患者中。在本研究中，我们旨在确定伊朗未接受拉米夫定治疗的慢性乙型肝炎患者中YMDD基序突变体的发生率。
共有77例未接受过拉米夫定治疗的慢性乙型肝炎患者纳入本研究。采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）检测患者血清样本中的YMDD基序突变体。所有患者还检测了肝酶、抗丙型肝炎病毒、HBeAg和抗HBe。
在纳入研究的77例患者中，73%为男性，27%为女性。平均谷丙转氨酶（ALT）和谷草转氨酶（AST）水平分别为124.4±73.4和103.1±81 IU/l。40%的患者HBeAg阳性，60%的患者抗HBe阳性。所有患者抗丙型肝炎病毒均为阴性。尽管患者存在肝酶水平异常以及HBeAg或抗HBe阳性，但未检测到任何患者有YMDD基序突变体。
虽然已有报道在未接受拉米夫定治疗的慢性乙型肝炎患者中自然出现YMDD基序突变体，但在伊朗未接受拉米夫定治疗的慢性乙型肝炎患者中未检测到这些突变体。
